Building the Bridge Between Clinical Research and Care
Building the Bridge Between Clinical Research and Care
ABOUT SITERX
ABOUT SITERX
Our Mission
Our Mission
SiteRx is on a mission to make clinical research accessible to all by improving transparency and diversity in clinical trials.
SiteRx is on a mission to make clinical research accessible to all by improving transparency and diversity in clinical trials.
We value compassion
We value compassion
We value security
We value security
We value reliability
We value reliability
STATS
STATS
About Alzheimer’s Disease
About Alzheimer’s Disease
6.7M
6.7M
Americans age 65 and older are living with Alzheimer’s dementia.
Americans age 65 and older are living with Alzheimer’s dementia.
6th
6th
leading cause of death in the US, and leading cause of disability and poor health in adults.
leading cause of death in the US, and leading cause of disability and poor health in adults.
41%
41%
of patients in the US reported knowing nothing about clinical trials.
of patients in the US reported knowing nothing about clinical trials.
73%
73%
of patients reported that their provider was their most trusted source of information on clinical trials.
of patients reported that their provider was their most trusted source of information on clinical trials.
HOW WE DO IT
HOW WE DO IT
Our Process
Our Process
We work with independent neurologists and providers across the US to facilitate efficient access to local clinical trials without the need of becoming a PI, running a research site, or hiring additional staff.
We work with independent neurologists and providers across the US to facilitate efficient access to local clinical trials without the need of becoming a PI, running a research site, or hiring additional staff.
GETTING STARTED
GETTING STARTED
Did You Know?
Did You Know?
While approved treatments may be few, 79% of Alzheimer’s disease drugs currently in clinical trials are targeting disease modification. As of January 1, 2023, 156 clinical trials were underway testing additional disease-modifying therapies.
While approved treatments may be few, 79% of Alzheimer’s disease drugs currently in clinical trials are targeting disease modification. As of January 1, 2023, 156 clinical trials were underway testing additional disease-modifying therapies.
ABOUT SITERX
ABOUT SITERX
Who We Are
Who We Are
Check out our patient explainer video to learn more about our process, our values, and our commitment to enhancing access to clinical trials for all patients and providers across the US.
Check out our patient explainer video to learn more about our process, our values, and our commitment to enhancing access to clinical trials for all patients and providers across the US.
Ready to Explore
Our Platform?
Ready to Explore
Our Platform?
Schedule a demo today with your dedicated SiteRx account representative.
Schedule a demo today with your dedicated SiteRx account representative.